- Home
- MTA vs MXCT Comparison
MTA vs MXCT Comparison
Compare MTA & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTA
- MXCT
- Stock Information
- Founded
- MTA 1983
- MXCT 1999
- Country
- MTA Canada
- MXCT United States
- Employees
- MTA N/A
- MXCT N/A
- Industry
- MTA
- MXCT Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- MTA
- MXCT Health Care
- Exchange
- MTA Nasdaq
- MXCT Nasdaq
- Market Cap
- MTA 279.4M
- MXCT 239.2M
- IPO Year
- MTA N/A
- MXCT 2021
- Fundamental
- Price
- MTA $3.90
- MXCT $2.24
- Analyst Decision
- MTA Hold
- MXCT Strong Buy
- Analyst Count
- MTA 1
- MXCT 1
- Target Price
- MTA $4.50
- MXCT $9.00
- AVG Volume (30 Days)
- MTA 465.4K
- MXCT 818.1K
- Earning Date
- MTA 08-13-2025
- MXCT 08-05-2025
- Dividend Yield
- MTA N/A
- MXCT N/A
- EPS Growth
- MTA N/A
- MXCT N/A
- EPS
- MTA N/A
- MXCT N/A
- Revenue
- MTA $6,348,000.00
- MXCT $37,675,000.00
- Revenue This Year
- MTA $125.91
- MXCT $8.82
- Revenue Next Year
- MTA $58.98
- MXCT $21.12
- P/E Ratio
- MTA N/A
- MXCT N/A
- Revenue Growth
- MTA 30.38
- MXCT N/A
- 52 Week Low
- MTA $2.32
- MXCT $2.00
- 52 Week High
- MTA $4.08
- MXCT $5.20
- Technical
- Relative Strength Index (RSI)
- MTA 63.93
- MXCT 48.95
- Support Level
- MTA $3.65
- MXCT $2.13
- Resistance Level
- MTA $3.94
- MXCT $2.32
- Average True Range (ATR)
- MTA 0.15
- MXCT 0.12
- MACD
- MTA 0.00
- MXCT 0.02
- Stochastic Oscillator
- MTA 79.55
- MXCT 74.37
About MTA Metalla Royalty & Streaming Ltd.
Metalla Royalty & Streaming Ltd is a precious metals royalty and streaming company, which engages in the acquisition and management of precious metal royalties, streams, and similar production-based interests. It's a pure-play gold and silver streaming and royalty company. It generates revenue from royalties, streams, and other interests.
About MXCT MaxCyte Inc.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.